GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Manhattan Scientifics Inc (OTCPK:MHTX) » Definitions » Cash Flow from Operations

Manhattan Scientifics (Manhattan Scientifics) Cash Flow from Operations : $-0.16 Mil (TTM As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Manhattan Scientifics Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2024, Manhattan Scientifics's Net Income From Continuing Operations was $-0.38 Mil. Its Depreciation, Depletion and Amortization was $0.00 Mil. Its Change In Working Capital was $0.15 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.00 Mil. And its Cash Flow from Others was $0.19 Mil. In all, Manhattan Scientifics's Cash Flow from Operations for the three months ended in Mar. 2024 was $-0.04 Mil.


Manhattan Scientifics Cash Flow from Operations Historical Data

The historical data trend for Manhattan Scientifics's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Manhattan Scientifics Cash Flow from Operations Chart

Manhattan Scientifics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.32 -0.39 -0.42 -0.35 -0.19

Manhattan Scientifics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.06 -0.04 -0.01 -0.04

Manhattan Scientifics Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Manhattan Scientifics's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Manhattan Scientifics's Cash Flow from Operations for the quarter that ended in Mar. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Manhattan Scientifics  (OTCPK:MHTX) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Manhattan Scientifics's net income from continuing operations for the three months ended in Mar. 2024 was $-0.38 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Manhattan Scientifics's depreciation, depletion and amortization for the three months ended in Mar. 2024 was $0.00 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Manhattan Scientifics's change in working capital for the three months ended in Mar. 2024 was $0.15 Mil. It means Manhattan Scientifics's working capital increased by $0.15 Mil from Dec. 2023 to Mar. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Manhattan Scientifics's cash flow from deferred tax for the three months ended in Mar. 2024 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Manhattan Scientifics's cash from discontinued operating Activities for the three months ended in Mar. 2024 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Manhattan Scientifics's asset impairment charge for the three months ended in Mar. 2024 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Manhattan Scientifics's stock based compensation for the three months ended in Mar. 2024 was $0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Manhattan Scientifics's cash flow from others for the three months ended in Mar. 2024 was $0.19 Mil.


Manhattan Scientifics Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Manhattan Scientifics's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Manhattan Scientifics (Manhattan Scientifics) Business Description

Traded in Other Exchanges
N/A
Address
244 Fifth Avenue, Suite 2341, New York, NY, USA, 10001
Manhattan Scientifics Inc is a company operating as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in the areas of nano-technologies and nano-medicines. The company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, and scientists and leaders in industry and government. The company is focused on technology transfer and commercialization of transformative technologies.
Executives
Chris Theoharis director 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Photios Frank Georgiou director 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Emmanuel Tsoupanarias director, officer: Chief Executive Officer 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Leonard Friedman director 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Marvin Maslow director, 10 percent owner, officer: Chief Executive Office MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022
David Teich director, officer: Treasurer MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022
Ralph Anderson director 641 FIFTH AVENUE SUITE 36F, NEW YORK NY 10022
Larry H Schatz director 152 W. 57TH STREET, 31ST FLOOR, NEW YORK NY 10019
Marty Steinberg 10 percent owner 1111 BRICKELL AVENUE SUITE 2500, MIAMI FL 33131
Scott Bach director, officer: Secretary MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022

Manhattan Scientifics (Manhattan Scientifics) Headlines

No Headlines